David Roodman G, Silbermann Rebecca
Department of Medicine, Hematology, Oncology, Indiana University , Indianapolis, IN, USA ; Richard L Roudebush VA Medical Center , Indianapolis, IN, USA.
Department of Medicine, Hematology, Oncology, Indiana University , Indianapolis, IN, USA.
Bonekey Rep. 2015 Oct 28;4:753. doi: 10.1038/bonekey.2015.122. eCollection 2015.
The bone is a frequent site for tumor metastasis, and cancer in the bone results in marked disturbances of bone remodeling that can be lytic, blastic or a combination of the two. Patients with advanced malignancies that have metastasized to the bone frequently suffer from debilitating skeletal-related events, including pathologic fractures, spinal cord compression syndromes, disorders of calcium and phosphate homeostasis and severe cancer-related pain. This review will discuss recent studies on the mechanisms responsible for osteolytic and osteoblastic metastasis and how their identification has resulted in the development of new agents for patients with metastatic bone disease.
骨骼是肿瘤转移的常见部位，骨癌会导致骨重塑明显紊乱，可表现为溶骨性、成骨性或两者兼具。已发生骨转移的晚期恶性肿瘤患者常遭受与骨骼相关的致残性事件，包括病理性骨折、脊髓压迫综合征、钙磷稳态紊乱以及严重的癌痛。本综述将讨论近期关于溶骨性和成骨性转移机制的研究，以及这些机制的确定如何促成了针对骨转移疾病患者的新型药物的研发。
